Ambuja Cements (AMBUJACEM) — Financial Results

Ambuja Cements reported record Q1 FY26 performance with sales volume of 18.4 million tonnes (up 20% YoY), revenue of ₹10,289 crores (up 23% YoY), and EBITDA of ₹1,961 crores (up 28% YoY, 19.1% margin). Market share increased to 15.5%. The company successfully integrated Orient Cement acquisition (April 2025) and commissioned 5 million tonnes of grinding capacity, now at 105 MTPA total capacity with 77-78% utilization. Organic volume growth (excluding acquisitions) reached 13% against industry growth of 4%. Management raised FY26 demand estimate from 6-7% to 7-8% and targets 140 MTPA by FY28, maintaining debt-free status with AAA rating.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AMBUJACEM ✨ Ask AI About This

About Ambuja Cements Limited (AMBUJACEM)

Construction Materials · Cement & Cement Products · Listed on NSE

Market Cap: ₹1,07,215.34 Cr P/E: 23.3 ROE: 7.7% ROCE: 4.6%

View full AMBUJACEM stock details →

📡 Get AI alerts when AMBUJACEM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AMBUJACEM — Free

💡 Ask AI about this filing

"How does this financial results affect Ambuja Cements Limited's outlook?" "What did Ambuja Cements Limited announce on 6 August 2025?" "Is this positive or negative for AMBUJACEM?"

Ask AI Free →

📊 More AMBUJACEM filings

See all AMBUJACEM filings →

🔥 Also filed on 6 August 2025

RECLTD REC Limited Financial Results SUNPHARMA Sun Pharmaceutical Industries Limited Financial Results TATAPOWER Tata Power Company Limited Financial Results TATASTEEL Tata Steel Limited Announcement TATASTEEL Tata Steel Limited Financial Results TRENT Trent Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AMBUJACEM files new disclosures

Track AMBUJACEM filings, board meetings, and corporate actions. Free email alerts at 5 PM.